Aliases & Classifications for Bone Disease

MalaCards integrated aliases for Bone Disease:

Name: Bone Disease 12 15 17
Bone Diseases 55 43 44 15 72
Disorder of Skeletal System 72
Skeletal Disorder 55
Skeletal Disease 12


External Ids:

Disease Ontology 12 DOID:0080001
MeSH 44 D001847
SNOMED-CT 68 76069003
ICD10 33 M89 M89.8 M89.9
UMLS 72 C0005940 C0263661

Summaries for Bone Disease

MedlinePlus : 43 Your bones help you move, give you shape and support your body. They are living tissues that rebuild constantly throughout your life. During childhood and your teens, your body adds new bone faster than it removes old bone. After about age 20, you can lose bone faster than you make bone. To have strong bones when you are young, and to prevent bone loss when you are older, you need to get enough calcium, vitamin D, and exercise. You should also avoid smoking and drinking too much alcohol. Bone diseases can make bones easy to break. Different kinds of bone problems include Low bone density and osteoporosis, which make your bones weak and more likely to break Osteogenesis imperfecta makes your bones brittle Paget's disease of bone makes them weak Bones can also develop cancer and infections Other bone diseases, which are caused by poor nutrition, genetics, or problems with the rate of bone growth or rebuilding NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Bone Disease, also known as bone diseases, is related to ischemic bone disease and osteopetrosis, and has symptoms including back pain, bone pain and sciatica. An important gene associated with Bone Disease is DANCR (Differentiation Antagonizing Non-Protein Coding RNA), and among its related pathways/superpathways are RANK Signaling in Osteoclasts and Osteoclast differentiation. The drugs Isosorbide Dinitrate and AT-101 have been mentioned in the context of this disorder. Affiliated tissues include bone, kidney and breast, and related phenotypes are cellular and growth/size/body region

Disease Ontology : 12 A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function.

Wikipedia : 75 Bone disease refers to the medical conditions which affect the... more...

Related Diseases for Bone Disease

Diseases related to Bone Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 769)
# Related Disease Score Top Affiliating Genes
1 ischemic bone disease 34.4 TNFSF11 TNFRSF11B TNFRSF11A SOST RUNX2 PTH
2 osteopetrosis 34.2 TNFSF11 TNFRSF11A CTSK
3 paget disease of bone 5, juvenile-onset 34.1 TNFSF11 TNFRSF11B TNFRSF11A CALCA
4 osteitis fibrosa 33.5 PTH CALCA BGLAP B2M
5 paget's disease of bone 33.3 TNFSF11 TNFRSF11B TNFRSF11A CALCA BGLAP B2M
6 osteonecrosis 33.2 TNFSF11 TNFRSF11B RUNX2 PTH BGLAP ACP5
7 bone inflammation disease 33.0 TNFSF11 TNFRSF11B CTSK BGLAP ACP5
8 hypophosphatasia 33.0 RUNX2 ALPP ALPL
9 arthropathy 32.9 TNFSF11 TNFRSF11B B2M
10 hypophosphatasia, adult 32.9 PTH CALCA BGLAP ALPL
11 primary hyperparathyroidism 32.7 VDR PTH FGF23 CALCA BGLAP ALPP
12 renal osteodystrophy 32.7 VDR TNFRSF11B SOST PTH FGF23 CALCA
13 cleidocranial dysplasia 32.4 RUNX2 BGLAP ALPL
14 osteopetrosis, autosomal recessive 7 32.4 TNFSF11 TNFRSF11A
15 osteopetrosis, autosomal dominant 2 32.3 TNFSF11 SOST CTSK BGLAP ACP5
16 osteomalacia 32.0 VDR PTH FGF23 CALCA BGLAP ALPL
17 enchondromatosis, multiple, ollier type 32.0 EXT2 EXT1 ACP5
18 myeloma, multiple 32.0 TNFSF11 TNFRSF11B FGFR3 DKK1 B2M
19 hyperparathyroidism 31.9 VDR TNFRSF11B PTH FGF23 CALCA BGLAP
20 rickets 31.7 VDR PTH FGF23 BGLAP ALPL
21 osteomyelitis 31.5 TNFSF11 CTSK ACP5
22 endosteal hyperostosis, autosomal dominant 31.5 TNFSF11 TNFRSF11B CTSK
23 kidney disease 31.5 VDR TNFRSF11B PTH FGF23 B2M
24 hypoparathyroidism 31.5 PTH FGF23 BGLAP ALPP
25 hypophosphatemia 31.4 PTH FGF23 BGLAP
26 hyperphosphatemia 31.4 VDR RUNX2 PTH FGF23
27 bone resorption disease 31.4 VDR TNFSF11 TNFRSF11B TNFRSF11A SOST RUNX2
28 uremia 31.3 VDR TNFRSF11B PTH B2M
29 fibrous dysplasia 31.3 FGF23 CALCA BGLAP
30 parathyroid adenoma 31.2 VDR PTH CALCA BGLAP
31 idiopathic hypercalciuria 31.2 VDR TNFSF11 BGLAP
32 hyperostosis 31.1 TNFRSF11B SOST FGF23
33 monoclonal gammopathy of uncertain significance 31.1 FGFR3 DKK1 B2M
34 familial expansile osteolysis 31.1 TNFSF11 TNFRSF11B TNFRSF11A
35 sclerosteosis 31.0 VDR SOST RUNX2
36 multicentric carpotarsal osteolysis syndrome 31.0 TNFSF11 TNFRSF11B TNFRSF11A CTSK BGLAP
37 glucocorticoid-induced osteoporosis 30.8 TNFSF11 TNFRSF11B RUNX2 PTH DKK1 CALCA
38 hypercalcemia, infantile, 1 30.8 VDR PTH CALCA
39 periodontitis 30.8 TNFSF11 TNFRSF11B RUNX2 CTSK BGLAP
40 giant cell tumor 30.8 TNFSF11 TNFRSF11B TNFRSF11A CTSK CALCA BGLAP
41 ankylosis 30.8 TNFRSF11B RUNX2 BGLAP
42 fibrogenesis imperfecta ossium 30.7 TNFRSF11B PTH CALCA
43 osteoporosis, juvenile 30.7 SOST PTH DKK1 CALCA BGLAP
44 rheumatoid arthritis 30.7 TNFSF11 TNFRSF11B TNFRSF11A CTSK ACP5
45 bone remodeling disease 30.6 VDR TNFSF11 TNFRSF11B TNFRSF11A SOST RUNX2
46 calciphylaxis 30.6 VDR PTH FGF23
47 aneurysmal bone cysts 30.6 TNFSF11 TNFRSF11A CALCA
48 osteogenesis imperfecta, type i 30.5 TNFRSF11B FGFR3 BGLAP
49 pfeiffer syndrome 30.5 RUNX2 FGFR3 BGLAP ALPL
50 bone giant cell tumor 30.5 TNFSF11 CTSK CALCA ACP5

Graphical network of the top 20 diseases related to Bone Disease:

Diseases related to Bone Disease

Symptoms & Phenotypes for Bone Disease

UMLS symptoms related to Bone Disease:

back pain, bone pain, sciatica, muscle cramp

MGI Mouse Phenotypes related to Bone Disease:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.3 ALPL B2M CTSK DKK1 EXT1 FGFR3
2 growth/size/body region MP:0005378 10.3 ALPL B2M CTSK DKK1 EXT1 FGF23
3 craniofacial MP:0005382 10.25 ALPL CTSK DKK1 EXT1 FGFR3 PTH
4 homeostasis/metabolism MP:0005376 10.18 ALPL B2M CTSK DKK1 FGF23 FGFR3
5 hematopoietic system MP:0005397 10.17 ALPL B2M CTSK FGF23 FGFR3 PTH
6 digestive/alimentary MP:0005381 10.15 ALPL B2M CTSK EXT1 FGF23 FGFR3
7 endocrine/exocrine gland MP:0005379 10.13 ALPL B2M CTSK FGF23 PTH RUNX2
8 immune system MP:0005387 10.11 ALPL B2M CTSK FGF23 FGFR3 PTH
9 limbs/digits/tail MP:0005371 10.07 ALPL CTSK DKK1 EXT1 FGF23 FGFR3
10 mortality/aging MP:0010768 9.97 ALPL B2M DKK1 EXT1 EXT2 FGF23
11 integument MP:0010771 9.92 B2M EXT1 FGF23 FGFR3 RUNX2 TNFRSF11A
12 respiratory system MP:0005388 9.56 ALPL CTSK DKK1 FGF23 FGFR3 RUNX2
13 skeleton MP:0005390 9.47 ALPL CTSK DKK1 EXT1 EXT2 FGF23

Drugs & Therapeutics for Bone Disease

Drugs for Bone Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 410)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
Lactulose Approved Phase 4 4618-18-2 11333
Tibolone Approved, Investigational Phase 4 5630-53-5
Mecasermin Approved, Investigational Phase 4 68562-41-4
Potassium Citrate Approved, Investigational, Vet_approved Phase 4
Gliclazide Approved Phase 4 21187-98-4 3475
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
Norelgestromin Approved, Investigational Phase 4 53016-31-2 13752005
Cobicistat Approved Phase 4 1004316-88-4
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
Methadone Approved, Illicit Phase 4 76-99-3 4095
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
Doxorubicin Approved, Investigational Phase 4 23214-92-8 31703
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Acetaminophen Approved Phase 4 103-90-2 1983
Desogestrel Approved Phase 4 54024-22-5 40973
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
Abatacept Approved Phase 4 332348-12-6 10237
Promethazine Approved, Investigational Phase 4 60-87-7 4927
alemtuzumab Approved, Investigational Phase 4 216503-57-0
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
Methyltestosterone Approved Phase 4 58-18-4 6010
Testosterone enanthate Approved Phase 4 315-37-7 9416
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
Mycophenolic acid Approved Phase 4 24280-93-1 446541
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
47 Tocotrienol Investigational Phase 4 6829-55-6
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
50 retinol Phase 4

Interventional clinical trials:

(show top 50) (show all 714)
# Name Status NCT ID Phase Drugs
1 Evaluation of Cholecalciferol Supplementation in Chronic Kidney Disease Patients With Restless Leg Syndrome Unknown status NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet
2 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus. Unknown status NCT02011620 Phase 4
3 Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs Unknown status NCT03023748 Phase 4 Intravenous Paricalcitol
4 Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 and Normal Protein Diet Virus Low Protein Diet in the Treatment of CKD-MBD and Malnutrition for Progressive CKD Patients Unknown status NCT02005302 Phase 4 1,25(OH)2 Vitamin D3;Vitamin D2
5 A Prospective Study of the InterFuse T(tm) Unknown status NCT02678130 Phase 4
6 A Multi-centre, Prospective, Randomised Trial of Short Course Alendronate Therapy or Placebo Combined With Vitamin D and Calcium to Prevent Loss of Bone Mineral Density in Antiretroviral-naïve, HIV-1 Infected Subjects Initiating Antiretroviral Therapy Unknown status NCT02322099 Phase 4 Alendronate;Placebo;Tenofovir disoproxil
7 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
8 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
9 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
10 Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid Completed NCT00172029 Phase 4 Zoledronic acid
11 An Open Label Study of the Efficacy, Safety, and Pharmacoeconomics of Oral Ibandronate (Bondronat 50 mg) in Treatment of Metastatic Bone Disease Completed NCT02564107 Phase 4 Ibandronate
12 Denosumab Counteracts Metabolic Bone Disease in Chronic Intestinal Failure Patients: A Randomized, Controlled Clinical Trial Completed NCT02853539 Phase 4 Denosumab
13 Osteopenia and Renal Osteodystrophy: Evaluation and Management Completed NCT00108394 Phase 4 pamidronate
14 Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Disodium Pamidronate in the Treatment of Bone Loss Associated With Liver Transplant Completed NCT00657852 Phase 4 Disodium pamidronate;Placebo
15 Comparison Between Pamidronate and Zoledronic Acid for the Treatment of Heart and Lung Transplant Related Osteopaenia and Osteoporosis Completed NCT00164008 Phase 4 zoledronic acid vs pamidronate
16 Pilot Study: Effects of Hectorol (Doxercalciferol) Vitamin D Replacement on Proteinuria, PTH Level and Bone Turnover in Stable Kidney Transplant Recipients: a Single-Blind, Placebo-Controlled Study in Patients Receiving 25-OH Vitamin D3 Completed NCT00889629 Phase 4 Doxercalciferol;placebo;25-OH Vitamin D3
17 A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease. Completed NCT00365131 Phase 4 Cerezyme (imiglucerase for injection)
18 A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of ICE Implant System Over 24 Months, for Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol Completed NCT01960361 Phase 4
19 An Open Label, Reclast®/Aclasta®, Re-treatment of Relapsed Patients With Paget's Disease of Bone Who Participated in the CZOL446K2304 and CZOL446K2305 Core Registration Studies Completed NCT00740129 Phase 4 Zoledronic Acid
20 A 2 Year Prospective, Multicentre, Open-label, Randomised, Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients (With a PTH > 150pg/ml) on a Ciclosporin A and Glucocorticoid Based Immunosuppressive Regimen. Completed NCT00738257 Phase 4 Pamidronate
21 An Open, Prospective, Multi-center Study to Evaluate Bone Loss, the Survival Rate of SPI Implant System and Implant Stability Over a 24 Months, in Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol. Completed NCT02367261 Phase 4
22 A 6 Months, Open-Label Phase IV Study to Confirm the Safety and Efficacy of Single Intravenous Dose of 5 mg Zoledronic Acid for the Patients of Paget's Disease of Bone (PDB) in China Completed NCT00774020 Phase 4 Zoledronic acid
23 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
24 Influence of Alfacalcidol on Falls in Elderly Postmenopausal, Alendronate-Treated, Osteopenic/Osteoporotic Women With High Risk of Falls Completed NCT00168909 Phase 4 alfacalcidol;placebo
25 A Randomized, Double-Blind, Multicenter, Parallel Pilot Clinical Trial to Study the Efficay of a Treatment of Lactulose + Vitamin D + Calcium 0.5 g Concurrently Controlled With a Standard Treatment (Vit D + Calcium) in Bone Mass Preservation Among Postmenopausal Women Completed NCT00160264 Phase 4 Lactulose, Vitamin D, Calcium
26 Double-blind, Placebo-controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of Oral Ibandronate Once Monthly in Postmenopausal Women With Osteopenia Completed NCT00129623 Phase 4 Placebo;ibandronate [Bonviva/Boniva]
27 A Multi-center, Post Marketing Surveillance Study to Monitor the Safety and Performance of the Barricaid® ARD in the Treatment of Back and Radicular Pain Caused by Primary Lumbar Disc Herniation Completed NCT01534065 Phase 4
28 A Prospective, Open-Label, Multi-Center, Two-Part Study to Investigate Patient Satisfaction With Monthly Dosed Ibandronate Therapy in Women With Post-Menopausal Osteoporosis or Osteopenia Transitioned From Once-Weekly Alendronate or Risendronate Completed NCT02604836 Phase 4 Ibandronate
29 Cholecalciferol Supplementation for Anemia and Mineral and Bone Disorder in Hemodialysis Patients (CHAMBER): A Multicenter, Double-blind, Randomized, Placebo-controlled Trial Completed NCT02214563 Phase 4
30 Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 in the Treatment of Chronic Kidney Disease Mineral and Bone Disease Completed NCT01633853 Phase 4 Vitamin D2;1,25(OH)2 Vit D3
31 Post US Approval Voluntary Registry Study to Determine Incidence of Hypocalcemia Post Reclast® Treatment in Patients With Paget's Disease After Institution of Educational Strategies to Improve Adherence to Calcium and Vitamin D Supplementation Completed NCT00668200 Phase 4 Reclast (ZOL446, zoledronic acid)
32 Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Completed NCT00772395 Phase 4 Risedronate;Placebo
33 An Open-Label, Multi-Center Study to Determine Level of Adherence to Monthly Oral or Every Three Month Intravenous Ibandronate Treatment in Post-Menopausal Women With Osteoporosis or Osteopenia, Who Are GI Intolerant of Daily or Weekly Alendronate or Risendronate Completed NCT02598453 Phase 4 Ibandronate
34 Switch From Tenofovir to Raltegravir for Low Bone Mineral Density Completed NCT00939874 Phase 4 Raltegravir
35 A Multinational, Randomized, Double-Blind, Parallel Group Comparative Trial on the Effects of 2 Years Treatment With Tibolone (1.25 mg Org OD 14) and Raloxifene (60 mg) on Bone Mineral Density in Osteopenic Postmenopausal Women Completed NCT00431431 Phase 4 tibolone;raloxifen
36 Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption? Completed NCT00766532 Phase 4 Aromatase Inhibitor
37 NMR Imaging and Stereological Analysis of Trabecular Bone in Female Subjects 60 and Older at Risk of Fracture Receiving Either Zoledronic Acid or Teriparatide Completed NCT01153425 Phase 4 Teriparatide;Zoledronic Acid
38 Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Completed NCT00504166 Phase 4 alendronate sodium
39 High Dosage Vitamin D in the Treatment of Osteoporosis in Postmenopausal Women Completed NCT00491920 Phase 4 cholecalciferol (Vitamin D3);placebo
40 Effect of Phosphate Binders on FGF-23 During Calcitriol Administration in CKD Stage 3 Patients Completed NCT01748396 Phase 4 Calcitriol;Calcium Carbonate
41 A Multicenter, Post-Approval Clinical Study for Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) Treatment for Patients With Hypophosphatasia (HPP) in Japan Completed NCT02531867 Phase 4
42 Open-Label Study to Establish the Short Term Efficacy of Intravenous Loading-Doses of Bondronat 6 mg in Patients With Breast Cancer and Skeletal Metastases Experiencing Moderate to Severe Pain, Within 7 Days After Initiation of Treatment Completed NCT02553707 Phase 4 Ibandronate
43 Efficacy of Monthly Ibandronate in Women With Rheumatoid Arthritis and Reduced Bone Mineral Density Receiving Long-term Glucocorticoids Completed NCT01287533 Phase 4 Ibandronate;Placebo
44 Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium- and Bone Metabolism After Successful Surgery? - Part I Completed NCT01222026 Phase 4 Strontium Ranelate + Ca/Vitamin-D;Placebo
45 Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability.A Comparison Between Vildagliptin and Gliclazide MR Completed NCT01679899 Phase 4 Vildagliptin;Gliclazide MR
46 A Randomized Placebo Controlled Double Blind Investigation of the Effects of Potassium Citrate on Bone Metabolism in Postmenopausal Osteopenia Completed NCT00357331 Phase 4 potassium citrate
47 A Randomized, Double-blind, Placebo-controlled, Phase IV Trial Evaluating the Palliative Benefit of Either Continuing Pamidronate or Switching to Second-line Zoledronic Acid in Breast Cancer Patients With High-risk Bone Metastases. Completed NCT01907880 Phase 4 Pamidronate;Zoledronic acid;placebo
48 A Phase 4 Randomized Multicenter Open Label Trial of Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3 or 4 Ckd Patients With Secondary Hyperparathyroidism Completed NCT00823303 Phase 4 Paricalcitol;Calcitriol
49 An Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis Completed NCT00035997 Phase 4 Zometa
50 Effect of Varied Dialysate Bicarbonate Levels on Phosphate and Potassium Removal: A Pilot Study Completed NCT01930370 Phase 4 Bicarbonate hemodialysis solution (low concentration);Bicarbonate hemodialysis solution (high concentration)

Search NIH Clinical Center for Bone Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :

deferoxamine mesylate

Cochrane evidence based reviews: bone diseases

Genetic Tests for Bone Disease

Anatomical Context for Bone Disease

MalaCards organs/tissues related to Bone Disease:

Bone, Kidney, Breast, Prostate, Bone Marrow, Liver, Lung

Publications for Bone Disease

Articles related to Bone Disease:

(show top 50) (show all 13241)
# Title Authors PMID Year
C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia. 17
31269546 2019
Evaluation of the spine is critical in the workup of recurrent instability after total hip arthroplasty. 17
31256675 2019
Transphyseal anterior cruciate ligament reconstruction in adolescents with substantial remaining growth causes temporary growth arrest resulting in subclinical leg-length discrepancy. 17
31261520 2019
[Significance of sRANKL/OPG ratio in diagnosis of multiple myeloma bone disease]. 9 38
20416172 2010
The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases. 9 38
19931437 2010
The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. 9 38
19660583 2010
Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. 9 38
19915614 2010
Osteopontin: an effector and an effect of tumor metastasis. 9 38
20205680 2010
Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma. 9 38
19862816 2010
Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling. 9 38
19782692 2010
Serum levels of total-RANKL in multiple myeloma. 9 38
19951882 2009
Bone biology and the role of the RANK ligand pathway. 9 38
20128323 2009
Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. 9 38
19587705 2009
Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors. 9 38
19201081 2009
RUNX2 mutations in Chinese patients with cleidocranial dysplasia. 9 38
19515746 2009
RANKL inhibition for the management of patients with benign metabolic bone disorders. 9 38
19558335 2009
The -9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPalpha and FOXA1 binding is associated with osteoporosis. 9 38
19371798 2009
RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. 9 38
19344283 2009
RANK, RANKL and osteoprotegerin in bone biology and disease. 9 38
19468919 2009
Role of RANKL in bone diseases. 9 38
19185505 2009
Cathepsin K: a therapeutic target for bone diseases. 9 38
19338743 2009
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. 9 38
19016581 2009
Clinical applications of RANK-ligand inhibition. 9 38
19356186 2009
Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn's disease. 9 38
19098682 2009
Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6. 9 38
18778854 2009
Targeting Src signaling in metastatic bone disease. 9 38
18942061 2009
Emerging treatments for postmenopausal osteoporosis - focus on denosumab. 9 38
19554095 2009
Action of RANKL and OPG for osteoclastogenesis. 9 38
19191757 2009
1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. 9 38
19449179 2009
[Long-term steroid therapy in children: is adjunct therapy relevant in nephrotic syndrome?]. 9 38
18951767 2008
Novel anti-cancer strategy in bone tumors by targeting molecular and cellular modulators of bone resorption. 9 38
18991786 2008
Negative regulation of the osteoblast function in multiple myeloma through the repressor gene E4BP4 activated by malignant plasma cells. 9 38
18829486 2008
Vitamin D receptor ligand therapy in chronic kidney disease. 9 38
18826852 2008
Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. 9 38
18829534 2008
RANKL inhibition in the treatment of bone metastases. 9 38
18685421 2008
Nutritional rickets and z scores for height in the United Arab Emirates: to D or not to D? 9 38
18937749 2008
Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis. 9 38
18369625 2008
Idiopathic severe elevation of serum alkaline phosphatase following adult renal transplantation: case reports. 9 38
18675129 2008
Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. 9 38
18312448 2008
Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease. 9 38
18038244 2008
Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). 9 38
18587716 2008
Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. 9 38
18294945 2008
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. 9 38
18057140 2008
A case of lethal hypophosphatasia providing new insights into the perinatal benign form of hypophosphatasia and expression of the ALPL gene. 9 38
17922851 2008
RANK ligand as a therapeutic target for bone metastases and multiple myeloma. 9 38
17964729 2008
Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. 9 38
17445976 2008
Bone disease drug discovery: examining the interactions between osteoblast and osteoclast. 9 38
18208371 2008
Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications. 9 38
17728092 2008
Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. 9 38
17905588 2008
Usefulness of a quick decalcification of bone sections embedded in methyl methacrylate[corrected]: an improved method for immunohistochemistry. 9 38
18095073 2008

Variations for Bone Disease

ClinVar genetic disease variations for Bone Disease:

# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 CACNA1G NM_018896.5(CACNA1G): c.664_666TTC[1] (p.Phe223del) short repeat Likely pathogenic rs730882202 17:48649319-48649321 17:50571958-50571960
2 SLC39A13 NM_001128225.3(SLC39A13): c.398C> T (p.Thr133Met) single nucleotide variant Conflicting interpretations of pathogenicity rs140574574 11:47433573-47433573 11:47412022-47412022
3 46;XY;t(7;12)(q21.13;q24)dn Translocation Uncertain significance

Copy number variations for Bone Disease from CNVD:

# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 43764 10 49062854 52062367 Duplication skeletal anomalies

Expression for Bone Disease

Search GEO for disease gene expression data for Bone Disease.

Pathways for Bone Disease

GO Terms for Bone Disease

Cellular components related to Bone Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 TNFSF11 TNFRSF11B SOST PTH FGFR3 FGF23
2 extracellular space GO:0005615 9.36 TNFSF11 TNFRSF11B SOST PTH FGF23 DKK1

Biological processes related to Bone Disease according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.95 TNFRSF11B PTH BGLAP B2M
2 cell-cell signaling GO:0007267 9.88 TNFRSF11A PTH FGFR3 CALCA
3 osteoblast differentiation GO:0001649 9.81 RUNX2 BGLAP ALPL
4 tumor necrosis factor-mediated signaling pathway GO:0033209 9.73 TNFSF11 TNFRSF11B TNFRSF11A
5 monocyte chemotaxis GO:0002548 9.7 TNFSF11 TNFRSF11A CALCA
6 osteoblast development GO:0002076 9.65 RUNX2 BGLAP
7 positive regulation of bone resorption GO:0045780 9.65 TNFSF11 TNFRSF11A
8 mammary gland alveolus development GO:0060749 9.64 TNFSF11 TNFRSF11A
9 heparan sulfate proteoglycan biosynthetic process GO:0015012 9.64 EXT2 EXT1
10 endochondral ossification GO:0001958 9.63 RUNX2 FGFR3 ALPL
11 cellular calcium ion homeostasis GO:0006874 9.62 VDR PTH
12 regulation of osteoclast differentiation GO:0045670 9.62 TNFSF11 BGLAP
13 vitamin D metabolic process GO:0042359 9.61 VDR FGF23
14 response to magnesium ion GO:0032026 9.61 TNFRSF11B FGF23
15 response to inorganic substance GO:0010035 9.6 TNFRSF11B BGLAP
16 negative regulation of bone resorption GO:0045779 9.59 TNFRSF11B CALCA
17 cellular response to vitamin D GO:0071305 9.58 FGF23 BGLAP
18 cellular response to parathyroid hormone stimulus GO:0071374 9.57 SOST FGF23
19 skeletal system development GO:0001501 9.56 VDR TNFRSF11B RUNX2 PTH FGFR3 EXT1
20 heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process GO:0015014 9.55 EXT2 EXT1
21 phosphate ion homeostasis GO:0055062 9.54 PTH FGF23
22 TNFSF11-mediated signaling pathway GO:0071847 9.51 TNFSF11 TNFRSF11A
23 bone mineralization GO:0030282 9.49 FGFR3 BGLAP
24 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.48 VDR FGF23
25 bone resorption GO:0045453 9.46 TNFSF11 PTH CTSK ACP5
26 positive regulation of fever generation by positive regulation of prostaglandin secretion GO:0071812 9.43 TNFSF11 TNFRSF11A
27 response to vitamin D GO:0033280 9.43 PTH BGLAP ALPL
28 positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling GO:0071848 9.4 TNFSF11 TNFRSF11A
29 cellular polysaccharide biosynthetic process GO:0033692 9.37 EXT2 EXT1
30 negative regulation of ossification GO:0030279 9.32 SOST DKK1
31 ossification GO:0001503 9.23 TNFSF11 TNFRSF11A SOST RUNX2 EXT2 EXT1
32 cell differentiation GO:0030154 10.03 VDR TNFSF11 RUNX2 FGF23 EXT2

Molecular functions related to Bone Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 alkaline phosphatase activity GO:0004035 9.26 ALPP ALPL
2 heparan sulfate N-acetylglucosaminyltransferase activity GO:0042328 9.16 EXT2 EXT1
3 glucuronosyl-N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase activity GO:0050508 8.96 EXT2 EXT1
4 N-acetylglucosaminyl-proteoglycan 4-beta-glucuronosyltransferase activity GO:0050509 8.62 EXT2 EXT1

Sources for Bone Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....